Jenny-Hoa Nguyen

Jenny-Hoa Nguyen

Auto-generated profile, based on publicly available information

Jenny-Hoa Nguyen

Department of Clinical Pharmacy, University of Michigan, Ann Arbor, MI, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JSJian Shi
Jian Shi
XWXinwen Wang
Xinwen Wang
JNJenny-Hoa Nguyen
Jenny-Hoa Nguyen
BBBarry E. Bleske
Barry E. Bleske
YLYan Liang
Yan Liang
HZHao-Jie Zhu
Hao-Jie Zhu

1 April 2016 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JSJian Shi
Jian Shi
XWXinwen Wang
Xinwen Wang
JNJenny Nguyen
Jenny Nguyen
AWAudrey H. Wu
Audrey H. Wu
BBBarry E. Bleske
Barry E. Bleske
HZHao-Jie Zhu
Hao-Jie Zhu
Sacubitril was recently approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure with reduced ejection fraction. As a prodrug, sacubitril must be metabolized (hydrolyzed) to its active metabolite sacubitrilat (LBQ657) to exert its intended therapeutic effects. Thus, understanding the determinants of sacubitril activation will lead to the improvement of sacubitril pharmacotherapy. The objective of this study was to identify the enzyme(s) responsible for the activation of sacubitril, and determine the impact of genetic variation on sacubitril activation. First, an incubation study of sacubitril with human plasma and the S9 fractions of human liver, intestine, and kidney was conducted. Sacubitril was found to be activated by human liver S9 fractions only. Moreover, sacubitril activation was significantly inhibited by the carboxylesterase 1 (CES1) inhibitor bis-(p-nitrophenyl) phosphate in human liver S9. Further incubation studies with recombinant human CES1 and carboxylesterase 2 confirmed that sacubitril is a selective CES1 substrate. The in vitro study of cell lines transfected with wild-type CES1 and the CES1 variant G143E (rs71647871) demonstrated that G143E is a loss-of-function variant for sacubitril activation. Importantly, sacubitril activation was significantly impaired in human livers carrying the G143E variant. In conclusion, sacubitril is selectively activated by CES1 in human liver. The CES1 genetic variant G143E can significantly impair sacubitril activation. Therefore, CES1 genetic variants appear to be an important contributing factor to interindividual variability in sacubitril activation, and have the potential to serve as biomarkers to optimize sacubitril pharmacotherapy.